Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma

Journal of Clinical Oncology

Volumn 32, Issue 8, 2014, Pages 760-767

  Hutson, Thomas E ^a   Escudier, Bernard ^b   Esteban, Emilio ^c   Bjarnason, Georg A ^d   Lim, Ho Yeong ^e   Pittman, Kenneth B ^f   Senico, Peggy ^g   Niethammer, Andreas ^g   Lu, Dongrui Ray ^g   Hariharan, Subramanian ^g   Motzer, Robert J ^h  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^d DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^e Samsung Medical Center   (South Korea)

^f QUEEN ELIZABETH HOSPITAL   (Australia)

^g PFIZER INC   (United States)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHENHYDRAMINE; SORAFENIB; SUNITINIB; TEMSIROLIMUS; ANGIOGENESIS INHIBITOR; CARBANILAMIDE DERIVATIVE; DRUG DERIVATIVE; INDOLE DERIVATIVE; MTOR PROTEIN, HUMAN; NICOTINAMIDE; PROTEIN KINASE INHIBITOR; PYRROLE DERIVATIVE; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE; VASCULOTROPIN RECEPTOR;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; CANCER GROWTH; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; COMPARATIVE EFFECTIVENESS; CONSTIPATION; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; DYSPHONIA; DYSPNEA; EPISTAXIS; FATIGUE; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPERCH; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; KIDNEY METASTASIS; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHRECTOMY; OPEN STUDY; OVERALL SURVIVAL; PATIENT HISTORY OF NEPHRECTOMY; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; SYSTEMIC THERAPY; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG ANTAGONISM; ENZYMOLOGY; KAPLAN MEIER METHOD; KIDNEY CARCINOMA; KIDNEY TUMOR; METABOLISM; METASTASIS; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MORTALITY; PATHOLOGY; TIME; TREATMENT FAILURE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; CARCINOMA, RENAL CELL; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INDOLES; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PYRROLES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIROLIMUS; TIME FACTORS; TOR SERINE-THREONINE KINASES; TREATMENT FAILURE; YOUNG ADULT;

EID: 84899679988     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.50.3961     Document Type: Article

References (24)

1. Escudier B, Eisen T, Stadler WM, et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134, 2007 (Pubitemid 46089673)
2. Escudier B, Pluzanska A, Koralewski P, et al: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet 370:2103-2111, 2007 (Pubitemid 350296300)
3. Rini BI, Halabi S, Rosenberg JE, et al: Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 26:5422-5428, 2008
4. Rini BI, Escudier B, Tomczak P, et al: Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial. Lancet 378:1931-1939, 2011
5. Sternberg CN, Davis ID, Mardiak J, et al: Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial. J Clin Oncol 28:1061-1068, 2010
6. Hudes G, Carducci M, Tomczak P, et al: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271-2281, 2007 (Pubitemid 46849157)
7. Motzer RJ, Escudier B, Oudard S, et al: Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 372:449-456, 2008
8. Motzer RJ, Escudier B, Oudard S, et al: Phase 3 trial of everolimus for metastatic renal cell carcinoma: Final results and analysis of prognostic factors. Cancer 116:4256-4265, 2010
9. Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124, 2007 (Pubitemid 46089672)
10. Motzer RJ, Hutson TE, Tomczak P, et al: Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27:3584-3590, 2009
11. Motzer RJ, Escudier B, Tomczak P, et al: Axitinib vs sorafenib for advanced renal cell carcinoma: Phase III overall survival results and analysis of prognostic factors. Presented at the European Society of Medical Oncology (ESMO), Vienna, Austria, September 28-October 2, 2012 (abstr 793PD)
12. Di Lorenzo G, Cartenì G, Autorino R, et al: Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. J Clin Oncol 27:4469-4474, 2009
13. Mackenzie MJ, Rini BI, Elson P, et al: Temsirolimus in VEGF-refractory metastatic renal cell carcinoma. Ann Oncol 22:145-148, 2011
14. Weikert S, Kempkensteffen C, Busch J, et al: Sequential mTOR inhibitor treatment with temsirolimus in metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitors. World J Urol 31:805-809, 2013
15. Garcia JA, Hutson TE, Elson P, et al: Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab. Cancer 116:5383-5390, 2010
16. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
17. Motzer RJ, Bacik J, Murphy BA, et al: Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20:289-296, 2002 (Pubitemid 34032623)
18. Heng DY, Mackenzie MJ, Vaishampayan UN, et al: Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: Clinical characteristics, risk factors, and subsequent therapy. Ann Oncol 23:1549-1555, 2012
19. Motzer RJ, Nosov D, Eisen T, et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: Results from a phase III trial. J Clin Oncol 31:3791-3799, 2013
20. Reference deleted
21. Armstrong AJ, George DJ, Halabi S: Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin. J Clin Oncol 30:3402-3407, 2012
22. Eisen T, Sternberg CN, Robert C, et al: Targeted therapies for renal cell carcinoma: Review of adverse event management strategies. J Natl Cancer Inst 104:93-113, 2012
23. Hutson TE, Bukowski RM, Cowey CL, et al: Sequential use of targeted agents in the treatment of renal cell carcinoma. Crit Rev Oncol Hematol 77:48-62, 2011
24. Sonpavde G, Choueiri TK, Escudier B, et al: Sequencing of agents for metastatic renal cell carcinoma: Can we customize therapy? Eur Urol 61:307-316, 2012